Does substituting oral anticoagulants with heparin between 6 and 12 weeks of gestation improve fetal outcomes without unacceptably increasing maternal thromboembolic risk in pregnant women with mechanical heart valves?
Anticoagulation in pregnant women with mechanical valves requires a careful balance between maternal thromboembolic risk and fetal embryopathy, highlighting a critical need for large prospective trials to define the optimal regimen.
Thromboembolic prophylaxis of women with mechanical heart valves during pregnancy is best achieved with OA; however, this increases the risk of fetal embryopathy. Substituting OA with heparin between 6 and 12 weeks reduces the risk of fetopathic effects, but with an increased risk of thromboembolic complications. The use of low-dose heparin is definitely inadequate; the use of adjusted-dose heparin warrants aggressive monitoring and appropriate dose adjustment. Large prospective trials to determine the best regimen for these women are needed.
Chan et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: